Genelux (GNLX) Cash from Investing Activities (2022 - 2026)
Genelux (GNLX) recorded quarterly Cash from Investing Activities of -$8.5 million in Q1 2026, down 230.09% quarter-over-quarter from $6.6 million in Q4 2025, and down 343.35% on a YoY basis from $3.5 million in Q1 2025.
Genelux (GNLX) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Genelux's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$8.5 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 343.35% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at $93000.0 (up 103.17% YoY), while the FY2025 annual figure was $12.1 million, up 249.32% from the prior year.
- Cash from Investing Activities was -$8.5 million for Q1 2026 at Genelux, down from $6.6 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $6.7 million in Q4 2024 to a low of -$17.1 million in Q2 2024.
- Historically, Cash from Investing Activities has averaged -$1.4 million across 5 years, with a median of -$193000.0 in 2023.
- Biggest YoY gain for Cash from Investing Activities was 1541.16% in 2024; the steepest drop was 4219.7% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$15000.0 in 2022, then slumped by 92846.67% to -$13.9 million in 2023, then surged by 147.87% to $6.7 million in 2024, then slipped by 1.65% to $6.6 million in 2025, then sank by 230.09% to -$8.5 million in 2026.
- The last three Cash from Investing Activities figures came in at -$8.5 million (Q1 2026), $6.6 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -8.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.54 Mn |
| Mar 31, 2026 | -8.54 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Sep 30, 2025 | 4.72 Mn |
| Sep 30, 2025 | 4.72 Mn |
| Jun 30, 2025 | -2.65 Mn |
| Jun 30, 2025 | -2.65 Mn |
| Mar 31, 2025 | 3.51 Mn |
| Mar 31, 2025 | 3.51 Mn |
| Dec 31, 2024 | 6.67 Mn |
| Dec 31, 2024 | 6.67 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Jun 30, 2024 | -17.11 Mn |
| Jun 30, 2024 | -17.11 Mn |
| Mar 31, 2024 | -1.69 Mn |
| Mar 31, 2024 | -1.69 Mn |
| Dec 31, 2023 | -13.94 Mn |
| Dec 31, 2023 | -13.94 Mn |